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A B S T R A C T
Intratumoral heterogeneity is a recently recognized but important feature of cancer that underlies the
various biocharacteristics of cancer tissues. The advent of next-generation sequencing technologies has
facilitated large scale capture of genomic data, while the recent development of single-cell sequencing
has allowed for more in-depth studies into the complex molecular mechanisms of intratumoral heter-
ogeneity. In this review, the recent advances and current challenges in single-cell sequencingmethodologies
are discussed, highlighting the potential power of these data to provide insights into oncological pro-
cesses, from tumorigenesis through progression to metastasis and therapy resistance.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Cancer remains as one of the world’s most lethal and debilitat-
ing diseases, despite massive research efforts to understand the
pathogenic processes and underlying molecular mechanisms. While
these studies have identiﬁed many features of cancer develop-
ment and progression, such as genetic mutations and pathogenic
phenotypes, they have also uncovered perplexing complexity in the
tumormicroenvironment, even the individual cells within the tumor
tissue showing distinctive phenotypes [1,2]. This newly recog-
nized feature is known as intratumoral heterogeneity and may
represent differing pathogenic potentials of tumor cells, where some
cells may represent a greater threat to the organism by having a
greater potential for metastasis or development of resistance to che-
motherapeutic drugs.
Applying single-cell sequencing technology to study the phe-
nomenon of intratumoral heterogeneity has uncovered its role in
cancer diagnosis and prognosis, as well as identifying factors that
may represent clinically useful diagnostic and/or prognostic
biomarkers and targets of molecular therapies [2]. The single-cell
sequencing technology is powerful and has the capability of cap-
turing dynamic genomic data for a single cancer cell under speciﬁc
cancer-related conditions, such as during the early stages of tumor
development or the late stages of metastasis. The resultant data may
help to deﬁne condition-related genetic proﬁles that underlie the
mechanisms of tumorigenesis, tumor progression, and develop-
ment of metastasis and resistance to various therapies [3–5].
One of the major technical challenges of single-cell sequencing
is the limited amount (picogram levels) of DNA and RNA in a single
tumor cell, which is below the threshold of sensitivity for even the
most advanced sequencing platforms. To overcome this limita-
tion, the nucleic acids from the isolated single cell must be ampliﬁed.
Thus, the current protocol for single-cell sequencing involves four
main steps: isolation of a single tumor cell, cell lysis, extraction of
nucleic acids, and ampliﬁcation. Each step, however, carries a po-
tential for error that limits the eﬃcacy and sensitivity of the
technology. The use of micropipetting, albeit common throughout
molecular biology experimental studies, is prone to operator error
and mechanical failure [6]. Isolation of single tumor cell for anal-
ysis is often carried out by ﬂuorescence activated cell sorting (FACS)
or magnetic activated cell sorting (MACS), both of which may alter
the transcriptional state of the cells [7], confounding the subse-
quent genomic analysis. The methods involved in the cell lysis and
extraction steps carry the risk of causing DNA or RNA degrada-
tion, sample loss, or contamination [6,8,9]. Finally, the current
methods used to amplify the low concentration of nucleic acids from
a single cell can yield non-uniform levels of ampliﬁcation prod-
ucts and inconsistent coverage of the original genomic information
[10,11].
The sequencing operation itself is also imperfect and even the
most advanced technological platforms have limited sensitivity, with
a threshold of resolution, and require operator expertise and lengthy
operation times, and the design and running of algorithms to in-
terpret the sequencing data [12,13]. Certainly, the use of single-
cell sequencing technology to describe the distinctive tumor-
related genetic proﬁles for various oncological processes will beneﬁt
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from research efforts to improve the sensitivity, eﬃciency and ra-
pidity of this analytical approach.
Herein, we provide a review of the methods and procedures of
single-cell sequencing (Fig. 1), including those that are more es-
tablished and those that have been newly developed, and discuss
their usefulness and limitations with the hope that this knowl-
edge will support the ongoing research efforts to improve this
technology and increase our knowledge in intratumor heterogeneity.
Isolation of single cells for sequencing
Isolating single cells from solid or liquid tumor tissues is the ﬁrst
and key step of single cancer cell sequencing. The following four
methods are the most commonly used for single-cell isolation, and
their primary characteristics are summarized in Table 1 [14].
Laser capture microdissection (LCM)
LCM is used to isolate individual cells from their native tissue
directly and without any chemical or physical destruction. The basic
procedure for LCM involves covering a section of the target tissue
with a thermoplastic ﬁlm and ﬁring a laser to melt the ﬁlm so that
it adheres to a single tumor cell and facilitates mechanical isola-
tion of that cell from its neighbors (Fig. 2A). Some researchers have
proposed the use of immunoﬂuorescence (i.e. ﬂuorescent-tagged
antibodies) to improve the speed and accuracy of this method
[15–17]. However, the LCM laser’s isolation of a single cell is still
not capable of completely clearing all microenvironment materi-
als’ strong adhesion junction from a target cell’s surface, which
represents a source of contaminating materials from neighboring
cells [18–20].
Micropipette isolation
The use of a micropipette to mechanically isolate a single cell
by aspiration is a cheap and technically simple method since the
only tools required are a basic micropipette and microscope with
relatively lower resolution (at the individual cell level). The basic
procedure for micropipette isolation involves enzymatic digestion
of the tumor tissue to acquire a cell suspension, after which the sus-
pension is diluted to approximately 10–20 cells per 1 μL solution
and examined under the microscope’s visual ﬁeld to select a single
cancer cell by micropipette-assisted aspiration (Fig. 2B). The limi-
tations of this procedure are the laborious nature of the technique,
resulting in low eﬃciency, and the dependence on the operator’s
expertise and low resolution visibility of the cells, making it highly
prone to mistakes in identifying truly individual cells or contami-
nating non-cancer cells [6,21,22]. Some researchers have proposed
the use of ﬂuorescence in situ hybridization (FISH) to improve the
eﬃciency of micropipette isolation [23].
Fluorescence-activated cell sorting (FACS)
The FACS platform is capable of both selecting and analyzing
single cells from a heterogeneous tumor tissue, relying on simul-
taneous analysis of ﬂuorescence signals and light scattering
parameters. The operational procedure of FACS involves disrup-
tion of the cancer tissue (either by enzymatic digestion ormechanical
disruption) to acquire a cell suspension, after which the target cells
are immunoreacted with one or more ﬂuorescence-tagged anti-
bodies targeting speciﬁc antigens on the cell surface or intracellular
markers; in this manner, speciﬁc cell types can be identiﬁed for iso-
lation and analysis. After processing, the antibody-labeled cells are
applied to a FACS machine in which they pass through a narrow
stream of ﬂuid with an intersecting laser beam that produces scat-
tered light signals according to the labeled cell characteristics. The
ﬂow of the cell-containing liquid can be regulated to ensure that
only one cell is present in a single droplet, and the light scattering
pattern will help to identify that cell; in addition, during the FACS
separation procedure, the cell will acquire temporary electrical prop-
erties that facilitate cell isolation (Fig. 2C) [24–26]. The FACS isolation
approach has been modiﬁed to use a panel of isotope-tags for the
immunoreactive antibodies [27].
The FACS isolation approach has several advantages over the LCM
and micropipette isolation procedures, including greater rapidity
and higher throughput. However, FACS detection of ﬂuorescent
signals is relatively low, and low-expression markers are diﬃcult
or impossible to detect [24], so that there is a risk of missing some
speciﬁc cell types.
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Fig. 1. Single-cell sequencing of a tumor cell. A tumor specimen is obtained by sur-
gical excision and single cells are isolated by one of the several methods shown in
Fig. 2. The individual cancer cell can be used for epigenome sequencing directly or
lysed to extract the genetic material (DNA and RNA), which is in turn ampliﬁed by
the methods shown in Fig. 3. Then, the ampliﬁed DNA and RNA are sequenced by
single-cell sequencing technology and the result data are analyzed to provide in-
sights into the molecular mechanisms underlying intratumor heterogeneity.
Table 1
Methods of isolating single cells for sequencing.
Method Sorting principle Single cell suspension Cost Throughput Automated? Limitation
Micropipette isolation Microexamination Yes Low Low No Operational bias
LCM Laser beam microdissection No High Low No Contamination by surrounding material
FACS Antigen–antibody hybrid Yes High High Yes Needs large numbers of cells
MACS Antigen–antibody hybrid Yes High High Yes Operational complexity
Abbreviations: LCM, laser capture microdissection; FACS, ﬂuorescence-activated cell sorting; MACS, magnetic-activated cell sorting.
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Magnetic-activated cell sorting (MACS)
MACS can capture and isolate single cells effectively and rapidly.
The operational procedure of MACS involves immunoreactivity of
antigens in the cell membrane and antibody conjunction with mag-
netic particles that allow for separation by magnetic ﬁelds (Fig. 2D)
[28,29]. MACS has been successfully applied to isolate individual
cells of different phenotypes from a variety of environments, and
has been especially useful in separating circulating tumor cells (CTCs)
from peripheral blood for use in cancer-related experimental re-
search [28,30].
Lysis of isolated single cancer cells for sequencing
After isolation of the single cancer cell, lysis is necessary to obtain
the genomicmaterial for sequencing; an ideal lysis methodwill min-
imize substrate dissipation and potential contamination, and induce
no changes to the genomic architecture that may inﬂuence down-
stream analyses. The currently available methods are either physics-
dependent or reagents-dependent, and decision for the appropriate
lysis method is made according to the downstream operation and
sample state; furthermore, more than one method can be used on
each sample [31–35].
The most common physics-dependent methods are optoelec-
tronic tweezers [36], sonication, nanoknives, electroporation and
freeze/thawing. The reagents-dependentmethods include detergent-
based lysis, alkaline lysis and enzymatic cell lysis [31,35]. Among
all the methods, alkaline lysis and Proteinase K digestion are the
most widely used in oncological studies for digestion of tumor tissues
[37–43].
The alkaline lysis method is carried out by placing the isolated
single cancer cell in phosphate-buffered saline, mixing in the al-
kaline lysis buffer, and incubating the solution for 10 minutes on
ice. The lysis action is stopped upon addition of a neutralizing buffer
[37,44,45]. In contrast, the proteinase K lysis protocol uses a solu-
tion consisting of proteinase K, 1× Tris–EDTA buffer and 1% Tween-
20; the single cancer cell is incubated in this solution for 3 hours
at 55 °C. Comparisons of these two reagent-dependentmethods have
shown that the proteinase K digestion is more eﬃcient than the al-
kaline lysis method when the cell number is lower than 100, and
that the former method produces less loss of nucleic acids due to
its pH being closer to the normal physiological level [21,31,37].
Nucleic acid (NA) extraction from single cancer cells for
sequencing
The currently available methods for NA extraction use either
column-based or solution-based protocols, and most of these are
available as convenient commercial kits [46]. The silica aﬃnity
binding column technology is the prototypical column-based
method, and has been applied frequently for the extraction of DNA
and RNA from single isolated tumor cells for subsequent sequenc-
ing [41,47–49]. The silica technology is based on the theory that high
aﬃnity exists between the positively-charged silica matrices and
the negatively-charged DNA backbone in high ionic strength solu-
tions; therefore, in this extraction approach DNA binds to silica and
can be readily eluted by washing with a low ionic strength buffer
[46,50]. This protocol has been made available as convenient com-
mercial kits, such as the AllPrep DNA/RNA kit (Qiagen) and the
Arcturus PicoPure RNA isolation kit (Applied Biosystems Inc.) [41,47].
Fig. 2. Methods for single-cell isolation. (A) In LCM, the tumor tissue is placed on a microscope slide and covered with a thermoplastic ﬁlm; a laser is beamed through the
ﬁlm, focused on the cell of interest, so that the ﬁlm adheres to the cell for isolation by mechanical dislocation from the tissue. In the next three methods (B–D), the tumor
tissue is ﬁrst digested into a cell suspension. (B) Micropipette aspiration uses a standard micropipette to mechanically capture the single cell from a cell suspension on a
microscope slide. (C) FACS detects the signal from ﬂuorescent dyes that are bound to the surface of a speciﬁc target cell. (D) MACS relies on the immunoreactivity of a cell
surface antigen with magnetic particles, so that the mixture can be sorted by a MACS Column placed in a MACS Separator. Abbreviations: LCM, laser capture microdissec-
tion; FACS, ﬂuorescence-activated cell sorting; MACS, magnetic-activated cell sorting.
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Microﬂuidics devices have been widely used for NA extraction,
and are especially useful with microquantities of DNA and RNA
[51–53]. The microﬂuidics device is usually a laminar device bound
by two opposing substrates; in the middle of the two substrates is
a channel. A solution containing labeled target materials is passed
through the channel and can be sorted during passage by applica-
tion of an exterior power source, such as a magnetic ﬁeld [52,54].
One of themost recently developedmicroﬂuidics methods is capable
of extracting and purifying bothmRNA and DNA from a single sample
(1–10 cells) simultaneously; this method, known by the acronym
SNARE (for “Selective Nucleic Acid Removal via Exclusion”), in-
volves contiguous wells in a line connected by a trapezoid channel,
consisting of an input well, followed by a middle well ﬁlled with
silicon oil, and two side-by-side output wells for the DNA andmRNA
outputs [9]. The input well is ﬁlled with a mixture of input mate-
rials (the cell lysis product), paramagnetic particles (PMPs; labeled
with oligo(dt)25) and lysis/binding buffer (which promotes the
binding of PMPs and mRNA). An external magnet is applied to pull
the mRNA- or DNA-bound PMPs (according to the charge of the
magnet) toward the front of the input well and through the middle
well until they enter the respective output well [9]. SNARE has been
successfully used to extract and purify DNA and RNA from pros-
tate cancer CTCs [9]. Moreover, the SNARE method is cost and time
eﬃcient, requires no hazardous chemicals, and has higher sensi-
tivity than other extraction methods [9].
Ampliﬁcation of genetic material from single cancer cells for
sequencing
Whole genome ampliﬁcation (WGA)
A normal diploid human cell contains approximately 6~7 pg of
DNA, which is inadequate for genomic sequencing using the cur-
rently available platforms [3,31]. Therefore, ampliﬁcation methods
are necessary and must be highly effective and low bias. The WGA
methods currently available are either based on temperature cycling
(routine PCR, PicoPLEX technology, multiple annealing and looping-
based ampliﬁcation cycles (MALBAC)) or isothermal conditions
(multiple displacement ampliﬁcation (MDA)) [10].
Routine PCR for WGA
Several PCR-based methods have been reported for WGA, in-
cluding the commonly used degenerate oligonucleotide primed PCR
(DOP-PCR) and primer extension preampliﬁcation-PCR (PEP-PCR).
The DOP-PCR reaction is carried out in two stages, each reliant
upon a distinctive primer corresponding to speciﬁc sequences for
ampliﬁcation [55]. The ﬁrst-stage primer is a semi-random priming
sequence, so that both tail ends of the primer can bind to multiple
sites in the genome and initiate ampliﬁcation at a low annealing
temperature [3,55,56]. The second-stage primer is a non-random
priming sequence, so that only fragments tagged by the speciﬁc se-
quence of the former primer are bound; this facilitates exponential
extension at a high annealing temperature (Fig. 3A) [55,56].
The PEP-PCR reaction is based on random priming and uses a
collection of 15-base random oligonucleotides as primers, allow-
ing for up to 415 different primers (Fig. 3B). After 50 primer-
extension cycles, no less than 30 copies of DNA should be produced,
and the coverage of genomic should be >78% at the single cell level
[57]. An improved version of this reaction, known as improved (I)-
PEP-PCR, was recently developed, in which a proofreading DNA
polymerase was added to the PEP-PCR reaction system in order to
remove any mismatched nucleotides at the 3′ ends of the random
primers. The I-PEP-PCR method has been shown to have remark-
ably better ampliﬁcation eﬃciency than either DOP-PCR or PEP-
PCR (40% vs. 15% or 3% at the single cell level) [58].
PicoPLEX technology for WGA
The PicoPLEX ampliﬁcation technology was speciﬁcally de-
signed to amplify DNA from a single cell by the use of a speciﬁc
primer in the traditional PCR reaction. The methodology involves
a DNA pre-ampliﬁcation stage followed by DNA ampliﬁcation
(Fig. 3C). In the ﬁrst stage, random primer extension is carried out
with non-complementary primers to amplify genomic DNA frag-
ments that are end-labeled with sequences that will facilitate
hybridization to single-stranded (ss) DNA for the subsequent PCR-
based ampliﬁcation. This protocol has been made available as a
convenient commercial kit, such as the PicoPLEX Single-Cell WGA
kit (New England Biolabs). It has been reported that the PicoPLEX
technology has a low level of inherent bias in ampliﬁcation but, in
comparison to the MDA approach (detailed below), is limited by a
higher sensitivity to background contamination [10].
Multiple annealing and looping-based ampliﬁcation cycles (MALBAC)
for WGA
MALBAC is a quasi-linear ampliﬁcation technology that com-
bines linear displacement ampliﬁcation methods with traditional
PCR to amplify the DNA fragments for use in downstream sequenc-
ing applications [3]. The ampliﬁcation process of MALBAC includes
a single cycle of four isothermal conditions followed by 20 cycles of
PCR ampliﬁcation [59]. The MALBAC primer consists of a 27-mer
common nucleotide sequence and eight variable nucleotides. In the
single cycle, the four isothermal conditions include DNA poly-
merase hybridizing to the templates at 0 °C, DNA polymerase-
mediated stranddisplacement generationof semi-amplicons at 65 °C,
DNA double-strands uncoiling at 94 °C, and complementary se-
quences from both ends of the full amplicons hybridizing to each
other to form looped DNAs at 58 °C, thereby preventing extra am-
pliﬁcation. Afterwards, traditional PCR is carried out on the full
amplicons for the 20 cycles (Fig. 3D) [60]. The MALBAC technique
has been successfully applied in oncological studies to facilitate am-
pliﬁcation of the whole genome of single CTCs obtained from lung
cancer and to determine the genomic proﬁles of cells in metastatic
cancer (providing data that distinguished primary cancer cells that
are likely to becomeCTCs) [60,61]. AlthoughMALBACprovides better
uniformity of genome coverage than other ampliﬁcation methods,
it also has a high false-positive rate when detecting heterozygous
loci and a high false-positive rate (40-fold higher than MDA) for
genotyping single-nucleotide variants [11,59,60].
Multiple displacement ampliﬁcation (MDA) for WGA
MDA is a non-speciﬁc ampliﬁcation method that relies on two
types of DNApolymerases,whichnot only bind to tandemDNAprod-
ucts generated by the single primer-initiated rolling circle ampli-
ﬁcation reaction but also can cause strand displacement; these types
of DNA polymerases include the Phi29 DNA polymerase and the Bst
large fragment DNA polymerase. TheMDAmethodology also relies
on a random primer that binds to multiple binding sites in the dis-
placed strand, thereby initiating complementary extension of the
ssDNA. Use of these two types of primer-initiated reactions pro-
duces contiguousdouble-strandedDNAproducts and formsanetwork
of hyperbranched DNA structures (Fig. 3E) [62,63]. Compared with
traditional PCR-based WGA, MDA has several advantageous fea-
tures, including the ability of Phi29DNApolymerase to catalyzeDNA
extension reactions at lowand constant temperatures and the ability
of the process to generate lengthy amplicons (up to 12 kb) [56,63,64].
However, theMDA approach is notwithout limitations, and the pro-
cedure is disadvantaged by nonhomogeneity of ampliﬁcation and
high allele dropout rate (which can reach up to 65%) [6,31,65].
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The more recently developed microwell displacement ampliﬁ-
cation system (MIDAS) can reduce the ampliﬁcation bias of MDA
by using a reduced reaction volume [66,67]. In MIDAS, the genetic
material from different cells (respectively placed in individual
nanoliter wells) is ampliﬁed simultaneously by MDA in the respec-
tive wells as single reaction chambers. In order to overcome the
potential problems of contamination (either exogenous or cross-
well), a ﬂuorescence label (e.g. SYBR Green I) has been included in
the MDA master mix to facilitate visualization of the ampliﬁca-
tion process via ﬂuorescence monitoring [44,63]. While MIDAS has
been successfully used to study copy number variation, due to its
excellent uniform genome coverage [44], it does not represent the
perfect solution to overcome all limitations of MDA and carries its
own limitations as well. The utilization rate of each microwell is
only 10%, which is necessary to avoid the potential problems posed
by more than one cell being present in the well, and the speed of
ampliﬁcation also remains suboptimal [44].
Whole transcriptome ampliﬁcation (WTA)
The amount of RNA in a single cell, which is at pictogram level,
cannot satisfy the requirements for analysis by the modern se-
quencing platforms, and WTA is necessary to perform single cell
transcriptome sequencing. The currently available methods of WTA
Fig. 3. Methods for whole-genome ampliﬁcation. (A) DOP-PCR uses a random primer extension stage followed by an exponential amplicon replication stage. (B) PEP-PCR
primers consist of 15-base random oligonucleotides, which are complementary to single strand template sequences and which can anneal at numerous positions in per-
missive thermocycling conditions. (C) PicoPLEX technology uses a speciﬁc primer that anneals to denatured DNA and initiates the extension reaction for 12 cycles, after
which the ampliﬁcation products are further ampliﬁed by PCR reaction for 14 cycles. (D) The MALBAC primer anneals to the single-strand DNA randomly, then synthesis of
a new strand is initiated by a polymerase with displacement activity. In the next ﬁve ampliﬁcation cycles, the DNA templates and semi-amplicons continue to extend, and
the 5′ and 3′ sequences of the full amplicons are hybridized to generate a looped DNA fragment so that further pre-ampliﬁcation is prevented. In the ﬁnal step, the PCR
reaction ampliﬁes the DNA loop. (E) MDA is an isothermal reaction, in which random oligonucleotide primers anneal to denatured DNA for DNA synthesis in the 5′ to 3′
direction reliant on the strand displacement activity of DNA polymerases. When the polymerase reaches any newly synthesized double-stranded DNA, the polymerase is
displaced to the newly synthesized strand to continue DNA polymerization.
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are based on traditional PCR, modiﬁed PCR, T7-in vitro transcrip-
tion (IVT) and Phi29 DNA polymerase-mediated RNA ampliﬁcation
[68,69].
Traditional PCR for WTA
The traditional PCR-based methods begin with reverse tran-
scription of the entire RNA of the cell, followed by rapid exponential
ampliﬁcation of the full-length cDNA [6,69]. The core principle of
this methodology involves binding of themRNA poly (A) tail to poly-
(dT) primers with different anchor sequences; unfortunately, this
feature precludes can not capture of mRNA without a poly (A) tail,
such as histonemRNA, and causes 5′ end bias when themRNA length
is over 3 kb since the anchor sequence binds to the 3′ end [69–71].
In addition, the non-linear ampliﬁcation will distort the initial rep-
resentation of transcripts, especially for the last several PCR cycles
[14].
Modiﬁed PCR for WTA
The modiﬁed PCR-based methods used to prepare the trans-
criptome for single-cell sequencing are also known as SMART tech-
niques (an acronym for “Switching Mechanism At the 5′ end of the
RNA Transcript”) that exploit the intrinsic reverse transcription and
template switching properties of theMoloneyMurine Leukemia virus
(MMLv) reverse transcriptase [72]. In SMART, a modiﬁed oligo (dT)
primer is used to initiate the reverse transcription reaction and a non-
template nucleotide sequence (consisting mainly of cytosines)
corresponding to the 3′ end of the new single-stranded cDNA, known
as the template-switching oligonucleotide, is annealed to the ssDNA
generated upon template-extension to facilitate PCR ampliﬁcation
[72–74]. However, this methodological approach is incapable of am-
plifying mRNAwithout the 5′ end and fragments of mRNA that have
only been partially reverse transcribed [69,74].
T7-IVT for WTA
The reverse transcription design of the primer used for the T7-
IVT-based methods of WTA is different from those of all the other
PCR-basedmethods. Several versions of this methodology have been
developed. For the one known as CEL-seq, an acronym for “cell ex-
pression by linear ampliﬁcation and sequencing”, the primer includes
an anchored poly-T, a unique barcode, the 5′ Illumina sequencing
adaptor, and a T7 promoter [75]; for the one known as Quartz-
Seq, the primer includes oligo-dT24, the T7 promoter, and the speciﬁc
sequences corresponding to the PCR target region [76]. The full pro-
cedure for the T7-IVT-based methods involves conversion of mRNA
to DNA, to RNA, and again back to DNA [74]. Compared with the
traditional PCR-based ampliﬁcation method, the T7-IVT-based
methods produce less accumulation of non-speciﬁc products, which
supports their improved speciﬁcity and ratio ﬁdelity [69,71,77];
however, the T7-IVT-based methods are more tedious and time-
consuming [69,75].
Phi29 DNA polymerase for WTA
The Phi29 DNA polymerase has long been used in WGA, and has
more recently been demonstrated as an effective tool for RNA am-
pliﬁcation [69,78]. The Phi29-mRNA ampliﬁcation (PMA) method
carries out RNA reserve transcription with the use of a poly-dT
primer, the subsequent cDNA ampliﬁcation is carried out with the
Phi29 DNA polymerase via the rolling circle ampliﬁcation process
[78]. A unique advantage of PMA is that it can achieve full-length
ampliﬁcation of all sizes of transcripts [69,78]; however, the genomic
DNA must be removed before ampliﬁcation to prevent its co-
ampliﬁcation [68,78].
A signiﬁcant obstacle to all WTA methods is how to protect the
intrinsic abundance of mRNA (without degradation) before and
throughout the extraction and puriﬁcation steps [6]. Moreover, the
current ampliﬁcation techniques for WTA (summarized in Table 2)
should be improved to increase eﬃciency and reduce bias.
Sequencing technologies for single-cell sequencing
First-generation sequencing technology
The so-called ‘ﬁrst-generation’ of sequencing technology is based
on automation of dideoxy Sanger sequencing. The advent of this au-
tomated platform rocketed the progression of biological sciences
and our approach to understanding normal physiological states and
managing pathological conditions. The core concept of Sanger’s
method involves termination of the extension of dsDNA upon in-
corporation of a dideoxyribonucleoside triphosphate (ddNTP) into
the extending DNA strand, with the termination point being de-
termined by the relative concentration of available ddNTPs and
dNTPs for this reaction. Unfortunately, the average length of Sanger’s
sequencing (up to 800 bases) is not adequate for WGS, and the la-
borious nature of the procedure (evenwhen automated) has resulted
in unacceptably high costs coupled with low throughput that limit
its utility [85,86].
Next-generation sequencing (NGS)
Efforts to overcome the shortcomings of the ﬁrst-generation se-
quencing technology culminated in the development of the NGS
technologies in widespread use today. In NGS, the genomic DNA is
sheared into millions of fragments, around 35–400 bp a piece, for
enmasse ampliﬁcation [87]; the ampliﬁcation approach varies among
the different NGS platforms. The three most widely used NGS plat-
forms are 454 Life Sciences/Roche, Illumina, and Applied Biosystems
Table 2
Methods for amplifying RNA for whole transcriptome analysis.
Method Year Principle Coverage Transcript lengths Limitation Ref
Tang’s method 2009 Traditional PCR 64% 0.5~3 kb 3′ end bias [6,14,70]
STRT-seq 2011 Modiﬁed PCR 5–25% 0.75~2.0 kb Strong 3′ end bias [3,69,73,79]
CEL-seq 2012 In vitro transcription 49% Average 1.0 kb Strong 3′ end bias, usually targets the last exons highly [14,69,75,76,80]
Smart-seq 2012 Modiﬁed PCR Nearly full-length Average 1.5 kb Cannot capture partially reverse-transcribed mRNA [69,80–82]
PMA 2013 Phi29 DNA polymerase Full-length All sizes Slight 5′ end bias [69,78]
SMA 2013 Traditional PCR Full-length All sizes Slight 5′ end bias [69,78]
Quartz–seq 2013 In vitro transcription 81% Average 2.5 kb 5′ end bias, cannot amplify cDNA with higher GC content [69,76,83]
Smart-seq2 2014 Modiﬁed PCR Nearly full-length ~2 kb Cannot capture poly A− RNA and reﬂects strand-speciﬁc mRNA [6,69,84]
Abbreviations: STRT, single-cell tagged reverse transcription; CEL-seq, cell expression by linear ampliﬁcation and sequencing; Smart-seq, switching mechanism at the 5′
end of the RNA template sequencing; PMA, Phi29 DNA polymerase-based mRNA transcriptome ampliﬁcation; SMA, semi-random primed PCR-based mRNA transcriptome
ampliﬁcation procedure.
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SOLiD systems [88,89], although the ﬁrst (454) has recently been
taken off the market (including manufacturing (in 2016)).
The 454 and Illumina NGS platforms were based on the
sequencing-by-synthesis (SBS) principle, while the SOLiD plat-
form was based on the principle of sequencing-by-ligation (SBL).
In SBS, light signals are generated by ﬂuorescent-labeled single nucle-
otides that are incorporated into the extending strand. The 454
system uses pyrosequencing, a procedure that involves the release
of a phosphate upon incorporation of a nucleotide which then ac-
tivates ﬁreﬂy luciferase to produce light [88]. In contrast, the Illumina
NGS system uses a unique cluster-ampliﬁcation method in which
adapter sequence-labeled DNA fragments are anchored to the surface
of ﬂow cell channels by binding with the corresponding sequences
of the speciﬁc adapters and ampliﬁed by bridge ampliﬁcation [87,90].
Sequencing of the ampliﬁed clusters involves incorporation of one
of the four labeled reversible terminating nucleotides, and the
imaging operation (i.e. reading of the sequence) is performed for
each single nucleotide incorporation with the labeled reversible ter-
minating nucleotide removed for the next incorporation by DNA
polymerase [87,88]. In SBL, no DNA polymerase is used; instead, DNA
ligase is used to match a known ﬂuorescent-labeled nucleotide to
an unknown nucleotide in a DNA fragment. In the SOLiD platform,
DNA fragments are bound to ﬂow cells, and ﬂuorescent-labeled
octamers are hybridized to the adaptor sequence for reading the
sequence by ﬂuorescence detection; while the ﬁrst ﬁve labeled-
nucleotides are integrated into the DNA sequence, only the ﬁrst two
can be identiﬁed and the other three (including the ones with a ﬂu-
orescence signal) are removed for the next cycle [88,89].
Although NGS has many advantages over the traditional Sanger
method and the ﬁrst-generation technology, including lower cost,
higher eﬃciency and lower background noise, it also has a sub-
stantially increased technical complexity, and requires a longer
running time due to the advanced algorithms that analyze and
process the enormous amounts of NGS data [13,91]. Furthermore,
the NGS platforms require high-level bioinformatics expertise, such
as that needed to develop and continually evolve effective data-
bases to interconnect phenotypic information with DNA variants
for clinical applications [86,92,93].
Third-generation sequencing (TGS)
Although NGS has proven incredibly useful in obtaining massive
amounts of genomic data from tissues, there still exist several limi-
tations when it is applied to single-cell sequencing, including
insuﬃcient resolution and read length, and unacceptable opera-
tion time and bias [12,94]. The next generation of sequencing
technology, known as TGS, is being designed to investigate single
molecules more accurately, such as nucleic acid sequencing of single
cancer cells. Three TGS systems are currently available and have
shown promising results from application; several TGS methods are
available, such as the Single-Molecule Real-Time (SMRT) sequenc-
ing technology, the Nanopore technology and the DNA transistor
technology [94].
SMRT sequencing is based on visualization of the second-strand
of DNA as it is synthesized and is based on the zero-modewave guide
measurement as it is affected by the delayed incorporation of a
ﬂorescent-labeled nucleotide by an anchored polymerase [94,95]. In
Nanopore sequencing, a polymerase is used to unzip the dsDNA and
feed the ssDNA through a charged nanopore; as a single nucleotide
goes through the pore, it disrupts the current in a characteristic
manner so that the molecule (and order of those molecules, such as
nucleotides in a sequence) can be identiﬁed by its pattern of current
disruption [94,96]. The DNA transistor technology also uses
nanometer-sized pores and reads the individual nucleotides of ssDNA
nucleotides according to their unique electronic signatures when
passing through the pores with an appropriate modulation [94].
Each of these TGS technologies has advantages over the NGS tech-
nologies, but none is perfect. The primary advantage of all these
technologies is low bias in genome coverage, even in high-GC regions,
because they can interrogate the single nucleotides without the bias
induced by ampliﬁcation [12,93,97]. Unfortunately, SMRT suffers from
low throughput and high raw read error rates [94], while the
Nanopore technology struggles with regulating the polymerase-
mediated passage of DNA through the pore [94,98]. The DNA
transistor technology has the advantage of rapidity, but it cannot
yet accurately regulate the miscibility of signals from neighboring
nucleotides [94,99,100].
Single-cell epigenomic detection
The most widely used methods to detect epigenetic proﬁles are
chromatin immunoprecipitation-sequencing (ChIP-Seq) and bisul-
ﬁte sequencing (BS-seq) [101]. ChIP, an enrichment-based approach,
is a well-established immunoreactive-based method that has been
widely used to detect (and measure, when coupled with quantita-
tive real-time PCR) epigenetic changes, and when coupled with
sequencing can detect genome-wide histonemodiﬁcations [101,102].
BS-seq can capture the DNA methylation status of cytosine resi-
dues (5-MeC) throughout the genome by performing double-
stranded DNA degeneration followed by bisulfate-induced conversion
of unmethylated cytosine to uracil and then performing PCR am-
pliﬁcation and data analysis [6,103,104]. Currently, BS-seq is
considered the gold standard for methylation analysis [102], but both
approaches are disadvantaged by their inherent limitation of only
being able to capture one feature at a time (and having high mon-
etary and labor costs for not being high-throughput) [101].
Several other novel methods for detecting epigenetic marks have
been reported but are not yet well established. Among them, SCAN
(the acronym for “Single Chromatin molecule Analysis in
Nanochannels”) is a nanoﬂuidic-based approach that can capture
more than one epigenetic feature of ssDNA and associated chro-
matin molecules [105], while iChmo (the acronym for “Imaging of
a Combination of Histone Modiﬁcations”) uses a dual hybridiza-
tion reaction of antigen–antibodies to capture two histone
modiﬁcation marks simultaneously [106].
Applications of single cell sequencing
Discovery of cancer-related genetic aberrations
Oncogenesis is a disease process manifesting frommultigene ab-
errations, which ultimately causes the transition of a normal cell
phenotype to an abnormal cell phenotype, such as that of a cancer
cell. Identifying the speciﬁc genetic aberrations underlying differ-
ent cancer types and different oncological stages (i.e. tumorigenesis,
metastasis, chemotherapy resistance) may help us to better under-
stand the mechanisms of tumor development and persistence as
well as to provide molecular targets for novel strategies of cancer
prevention and therapy.
Recently, a whole-exome sequencing project involving 22 gastric
cancer samples was performed [107], and 7036 somatic muta-
tions were measured, including 4653 located in coding regions or
essential splice sites. All except 59 of the affected genes harbored
protein-altering somatic mutations, and 2831 new genes were de-
tected as mutated in the gastric cancer condition. Moreover, 20 new
geneswere identiﬁed as having potential for promoting gastric cancer
(gastric cancer-driver genes), with low false discovery rate (FDR ≤ 0.2).
The authors also performed Sanger sequencing of one of these new
genes, ARID1A, in specimens from 109 gastric cancer cases and found
that 39 of these carried either a single or double mutation; in
addition, they determined that the mutation rate of ARID1A was
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different among the different molecular subtypes of gastric cancers
examined [107].
Transcriptome and epigenome sequencing data are also impor-
tant for uncovering cancer-related aberrations. A transcriptome
analysis of colorectal cancer CTCs revealed that the CTCs may rep-
resent a state of dormancy since the cancer-related down-regulated
transcripts were associated with genes that play a role in “stemness”,
such as CD166 (ALCAM) and CD26 (DPP4). In addition, some of the
genes that showed lower expression in the colorectal cancer CTCs
are known to play roles in cell–cell contact and motility. The only
upregulated gene found in these colorectal cancer CTCs was CD47,
which has been proposed to help cancer cells escape immune-
killing [41]. In addition, several genes that play important roles in
normal cellular functions, such as Septin 9 (SEPT9), POU4F1 andNOL4
(nucleolar protein 4), have been demonstrated as having cancer-
related epigenetic modiﬁcations, such as those at the CpG islands,
which may contribute to the tumorigenic mechanism [108–111].
Reconstructing cancer cell lineage trees
Cancer evolution usually involves the accumulation of genetic
aberrations, which act to disrupt the function of normal cells and
promote the transition to a carcinoma phenotype [112]. Captur-
ing these genetic aberrations, both as spatial and temporal data, will
allow for the reconstruction of cancer cell lineage trees so that the
evolutionary process of cancer can be analyzed and can provide in-
sights into the diagnosis and treatment of this disease.
Various models have been developed to construct such cancer
cell lineage trees using sequencing data, including that from single-
cell sequencing. The minimal spanning tree method can accom-
modate sequencing errors to order all the mutations sites from the
sequencing data. In the mutation tree itself, the early mutation sites
are placed in the root, while other mutations are placed in differ-
ent layers, with the branching architecture depending on the relative
distances. In this approach, a novel algorithm model is used to es-
timate the time it took for a proportion of mutations to have
accumulated, from the ﬁrst mutation to the most recent common
ancestor mutation. Unfortunately, this bioinformatics method is
limited by the precision of the currently available single-cell se-
quencing technologies [113].
The PhyloSub statistical model divides cancer cells into several
major subclonal lineages and estimates their ancestry according to
the presence of single-nucleotide variants (SNVs) and allele fre-
quencies, as determined from sequencing data. When the clonal
frequencies are insuﬃcient to reconstruct the phylogeny, theMarkov
Chain Monte Carlo (MCMC) method can be used to capture the
“partial order plot” for inferring the phylogenetic relationships. The
PhyloSub model is also applicable to research of the various somatic
mutations, such as small insertions and deletions; however, the hin-
drance to constructing cancer cell lineage trees is the unknown of
how many cells are involved in the research, so it can cover all the
single nucleotide mutations [6].
Although the research based on tumor cell lineage tree con-
struction has provided some very important insights into the
processes of cancer development and progression, the power of this
approach remains limited by the currently available algorithms for
analyzing sequencing data and the high error rate generated during
the sequencing process.
Cancer diagnosis and therapy
The accumulated genetic aberrations that underline tumorigen-
esis can also mediate the tumor cell’s response to therapy [114].
Single-cell sequencing technology may identify markers related to
cancer diagnosis as well as molecules that will act as targets for in-
dividualized therapy [115,116].
Various cancer-related mutations are already in clinical used as
biomarkers for the detection of cancer in general and diagnosis of
speciﬁc cancer types, including the BRAF mutations of melanoma,
the KRASmutations of colon cancer, and the epidermal growth factor
receptor (EGFR) mutations of non-small-cell lung cancer [116].
However, these biomarkers are only sensitive enough for use as in-
dicators and deﬁnitive diagnoses require more detailed and
comprehensive analyses, as no single mutation to date has been ab-
solutely correlatedwith a speciﬁc cancer type and stage or prognosis.
For example, while the NOL4 (Nucleolar protein 4) gene and the
LHFPL4 (lipoma HMGIC fusion partner-like protein 4) gene have been
observed as having high-frequency methylation in many cervical
cancer cases [105,110,111], the smaller percentage of cases that do
not show this proﬁle would be missed by a diagnostic approach
relying solely on these markers.
It has been proposed that the cancer phenotype may be re-
stored to a normal phenotype by modifying the cancer-related
genetic aberrations. Various targeting drugs capable of inhibiting
the function of the abnormal gene are available and some have been
used in clinic trials as individualized cancer treatments, such as the
histone deacetylase inhibitors for hematological malignancies, the
BRAF inhibitors for melanoma, and the PARP inhibitors for breast
cancer [116–119]. These targeted drugs do not appear to be a general
answer to all cancer types, as they have been shown to exert dif-
ferent effects in different or even the same kinds of cancers, because
the cancers can hardly be the result of the same genetic aberra-
tions [118]. Single-cell sequencing to uncover the distinctive panels
of genetic aberrations in various cancer types and stages will likely
help improve this type of therapeutic approach.
Conclusion and future perspectives
The cell is the functional unit of an organism; in multi-celled or-
ganisms, such as humans, the heterogeneity that inherently exists
among its individual cells involves both the phenotype and geno-
type levels. Single-cell sequencing technology provides an unpre-
cedented methodology for cancer research, allowing for the analy-
sis that is present among heterogeneous cancer cell populations at
the single cell level. The data from single-cell sequencingwill advance
our understanding of cancer pathogenesis, so that improvedmethods
of diagnosis and treatmentmay be developed; in addition, these data
will act as foundational information for further research studies, such
as those to reconstruct the cancer cell evolution lineage.
The tools that support single-cell sequencing, including re-
agents, equipment and bioinformatics algorithms, are continually
being reﬁned to increase the power of this platform. The recent tech-
nological advances have allowed for both DNA and RNA to be
extracted simultaneously from a single sample [9] and have de-
creased the ampliﬁcation bias (such as with the newly introduced
MIDAS approach by reducing the reaction volume of MDA [44]).The
ongoing efforts of the sequencing research community at large will
almost certainly culminate in innovative approaches for the third
generation of sequencing technology, especially for the single-
molecule sequencing approach [94]. Moreover, these efforts will
include generation of more sophisticated deﬁcient algorithms to
process and interpret the single-cell sequencing data [113,120–122].
The creation of an optimal single-cell sequencing technologymust
overcome the numerous limitations that currently exist for the
various tools involved. Signiﬁcant challenges are still posed by con-
tamination [21], ampliﬁcation bias (for both DNA and RNA) [11,14],
eﬃciency of sequencing [94], and algorithms advanced enough to
link the sequencing data [113,120]. Improved single-cell sequenc-
ing technologies will decrease or even eliminate these challenges
so that more precise sequencing data will be obtained and the
relationship between sequencing data and pathological features will
be convenient and accurate.
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